Preferred Label : Adenoviral Brachyury Vaccine ETBX-051;
NCIt related terms : ETBX-051; Ad5-brachyury vaccine;
NCIt definition : A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus
(Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted,
and the human transcription factor brachyury encoded, with potential immunostimulating
and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury
vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce
a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing
brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation
and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus
immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box
family of transcription factors, is overexpressed in a variety of tumor types. It
plays an important role in cancer progression and metastasis.;
UNII : BPG11IF0HW;
CAS number : 2171537-82-7;
Molecule name : ETBX 051; ETBX-051;
NCI Metathesaurus CUI : CL541478;
Origin ID : C143034;
UMLS CUI : C4688501;
Semantic type(s)
- concept_is_in_subset
- has_target
